Details for New Drug Application (NDA): 202836
✉ Email this page to a colleague
NDA 202836 describes LISDEXAMFETAMINE DIMESYLATE, which is a drug marketed by Actavis Elizabeth, Alkem Labs Ltd, Amneal, Apotex, Ascent Pharms Inc, Hikma, Lannett Co Inc, Mylan, Norwich, Prinston Inc, Rhodes Pharms, Sandoz, Specgx Llc, Sun Pharm Inds Inc, MSN, and Teva Pharms, and is included in eighteen NDAs. It is available from sixteen suppliers. Additional details are available on the LISDEXAMFETAMINE DIMESYLATE profile page.
The generic ingredient in LISDEXAMFETAMINE DIMESYLATE is lisdexamfetamine dimesylate. Seventeen suppliers are listed for this compound. Additional details are available on the lisdexamfetamine dimesylate profile page.
The generic ingredient in LISDEXAMFETAMINE DIMESYLATE is lisdexamfetamine dimesylate. Seventeen suppliers are listed for this compound. Additional details are available on the lisdexamfetamine dimesylate profile page.
Summary for 202836
| Tradename: | LISDEXAMFETAMINE DIMESYLATE |
| Applicant: | Sandoz |
| Ingredient: | lisdexamfetamine dimesylate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 202836
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 20MG | ||||
| Approval Date: | Jul 26, 2024 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 30MG | ||||
| Approval Date: | Jul 26, 2024 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 40MG | ||||
| Approval Date: | Jul 26, 2024 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
